Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
August 14 2023 - 4:30PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of August 2022
001-40614
(Commission
File Number)
INTERCURE
LTD.
(Exact
name of Registrant as specified in its charter)
85
Medinat ha-Yehudim Street
Herzliya,
4676670, Israel
Tel:
+972 77 460 5012
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
On
August 14, 2023, a Special General Meeting of Shareholders of InterCure Ltd. (the “Company”) approved the proposal brought
before the Company’s shareholders at the meeting, in accordance with the majority required for the proposal. The said proposal
was described in the Company’s Notice of Special Meeting of Shareholders with respect to the Company’s Special General Meeting
of Shareholders, dated July 10, 2023, attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities
and Exchange Commission on July 24, 2023.
In
addition, following approval by the Toronto Stock Exchange (the “TSX”) of the Company’s request to delist its ordinary
shares, no par value (the “Ordinary Shares”) from trading on the TSX, the last day for trading of the Company’s Ordinary
Shares on the TSX was August 14, 2023.
The
Company’s Ordinary Shares will continue to be traded on the Nasdaq Capital Market (the “Nasdaq”) and the Tel Aviv Stock
Exchange (the “TASE”), in each case, under the symbol “INCR.”
The
Company will continue to file public reports and make public disclosures in accordance with the rules and regulations of the U.S. Securities
and Exchange Commission and Nasdaq. The delisting in Canada will not affect the Company’s continued listing on the Nasdaq
and the TASE.
The
Company’s Ordinary Shares will be dual listed on the Nasdaq and on TASE, in accordance with Section 35FF of the Israeli Securities
Law, 5728-1968 (the “Securities Law”). The Company will continue its reporting obligations in Israel in accordance with the
provisions of Chapter 5C of the Securities Law, except that the Company will follow the reporting regime of the Nasdaq, in lieu of the
reporting regime of the TSX.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date:
August 14, 2023 |
By: |
/s/
Amos Cohen |
|
|
Amos
Cohen |
|
|
Chief
Financial Officer |
Intercure (NASDAQ:INCR)
Historical Stock Chart
From Apr 2024 to May 2024
Intercure (NASDAQ:INCR)
Historical Stock Chart
From May 2023 to May 2024